{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:24:11Z","timestamp":1790958251344,"version":"4.1.0"},"reference-count":63,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1097\/wco.0b013e32833045a0","type":"journal-article","created":{"date-parts":[[2009,9,15]],"date-time":"2009-09-15T03:15:29Z","timestamp":1252984529000},"page":"506-515","source":"Crossref","is-referenced-by-count":39,"title":["Agents and mechanisms of toxic myopathy"],"prefix":"10.1097","volume":"22","author":[{"given":"Ralph W","family":"Kuncl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-11-20210206","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/mus.10244","article-title":"Iatrogenic and toxic myoapathies","volume":"27","author":"Seib","year":"2003","journal-title":"Muscle Nerve"},{"key":"R3-11-20210206","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.ncl.2004.12.014","article-title":"Toxic myopathies","volume":"23","author":"Walsh","year":"2005","journal-title":"Neurol Clin"},{"key":"R4-11-20210206","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/WCO.0b013e32830e2774","article-title":"Drug-induced myopathies","volume":"21","author":"Klopstock","year":"2008","journal-title":"Curr Opin Neurol"},{"key":"R5-11-20210206","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","article-title":"Statin-associated myopathy","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA"},{"key":"R6-11-20210206","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.amjmed.2008.06.043","article-title":"Statin-induced myopathy: hypothesis about randomized evidence and clinical impressions","volume":"122","author":"Hennekens","year":"2009","journal-title":"Am J Med"},{"key":"R7-11-20210206","doi-asserted-by":"crossref","first-page":"52C","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review","volume":"97","author":"Law","year":"2006","journal-title":"Am J Cardiol"},{"key":"R8-11-20210206","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/00001648-200109000-00017","article-title":"Lipid-lowering drugs and risk of myopathy: a population-based follow-up study","volume":"12","author":"Gaist","year":"2001","journal-title":"Epidemiology"},{"key":"R9-11-20210206","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/pds.1535","article-title":"Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis","volume":"17","author":"McAdams","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R10-11-20210206","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.amjcard.2005.12.008","article-title":"Statin safety: an appraisal from the Adverse Event Reporting System","volume":"97","author":"Davidson","year":"2006","journal-title":"Am J Cardiol"},{"key":"R11-11-20210206","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.clinthera.2006.01.005","article-title":"Statin-related adverse events: a meta-analysis","volume":"28","author":"Silva","year":"2006","journal-title":"Clin Ther"},{"key":"R12-11-20210206","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1021\/jm800001n","article-title":"(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1H-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitor with reduced myotoxicity potential","volume":"51","author":"Ahmad","year":"2008","journal-title":"J Med Chem"},{"key":"R13-11-20210206","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy: a genomewide study.","volume":"359","year":"2008","journal-title":"N Engl J Med"},{"key":"R14-11-20210206","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0303-8467(93)90122-W","article-title":"Rhabdomyolysis: a review of the literature","volume":"95","author":"Poels","year":"1993","journal-title":"Clin Neurol Neurosurg"},{"key":"R15-11-20210206","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1161\/01.CIR.0000032466.44170.44","article-title":"ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins","volume":"106","author":"Pasternak","year":"2002","journal-title":"Circulation"},{"key":"R16-11-20210206","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1080\/01926230590908213","article-title":"Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity","volume":"33","author":"Westwood","year":"2005","journal-title":"Toxicol Pathol"},{"key":"R17-11-20210206","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0163-7258(99)00045-5","article-title":"New insights into the pharmacodynamic and pharmacokinetic properties of statins","volume":"84","author":"Corsini","year":"1999","journal-title":"Pharmacol Ther"},{"key":"R18-11-20210206","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.lfs.2008.02.019","article-title":"Association between risk of myopathy and cholesterol lowering effect: a comparison of all statins","volume":"82","author":"Kobayashi","year":"2008","journal-title":"Life Sci"},{"key":"R19-11-20210206","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/bjp.2008.192","article-title":"Involvement of organic anion transporting polypeptides in the toxicity of hydrophilic pravastatin and lipophilic fluvastatin in rat skeletal myofibres","volume":"154","author":"Sakamoto","year":"2008","journal-title":"Br J Pharmacol"},{"key":"R20-11-20210206","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1006\/taap.1997.8131","article-title":"Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro","volume":"145","author":"Flint","year":"1997","journal-title":"Toxicol Appl Pharmacol"},{"key":"R21-11-20210206","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2008.05.021","article-title":"Molecular basis of statin-associated myopathy","volume":"202","author":"Vaklavas","year":"2009","journal-title":"Atherosclerosis"},{"key":"R22-11-20210206","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1006\/taap.1997.8174","article-title":"HMG Co-A reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell cultures","volume":"145","author":"Flint","year":"1997","journal-title":"Toxicol Appl Pharmacol"},{"key":"R23-11-20210206","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/0009-9236(95)90266-X","article-title":"Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans","volume":"57","author":"Laaksonen","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"R24-11-20210206","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0002-9149(97)89180-1","article-title":"The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle","volume":"77","author":"Laaksonen","year":"1996","journal-title":"Am J Cardiol"},{"key":"R25-11-20210206","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/MOL.0b013e3283168ecd","article-title":"Effects of ubiquinone (coenzyme Q10) on myopathy in statin users","volume":"19","author":"Schaars","year":"2008","journal-title":"Curr Op Lipidol"},{"key":"R26-11-20210206","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/00005072-199309000-00012","article-title":"Experimental lovastatin myopathy","volume":"52","author":"Waclawik","year":"1993","journal-title":"J Neuropathol Exp Neurol"},{"key":"R27-11-20210206","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.taap.2003.08.013","article-title":"Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal muscle myopathy in rats","volume":"194","author":"Schaefer","year":"2004","journal-title":"Toxicol Appl Pharmacol"},{"key":"R28-11-20210206","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/0022-510X(92)90273-N","article-title":"Experimental simvastatin-induced myopathy in rabbits","volume":"113","author":"Nakahara","year":"1992","journal-title":"J Neurol Sci"},{"key":"R29-11-20210206","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","article-title":"Statin-associated myopathy with normal creatine kinase levels","volume":"137","author":"Phillips","year":"2002","journal-title":"Ann Intern Med"},{"key":"R30-11-20210206","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1124\/jpet.106.118331","article-title":"Fluvastatin and atorvastatin affect calcium homeostasis of rat skeletal muscle fibers in vivo and in vitro by impairing the sarcoplasmic reticulum\/mitochondria Ca2+-release system","volume":"321","author":"Liantonio","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"R31-11-20210206","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.coph.2007.12.010","article-title":"New insights into mechanisms of statin-associated myotoxicity","volume":"8","author":"Sirvent","year":"2008","journal-title":"Curr Op Pharmacol"},{"key":"R32-11-20210206","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1056\/NEJMe0805136","article-title":"Pharmacogenomics and drug toxicity","volume":"359","author":"Nakamura","year":"2008","journal-title":"N Engl J Med"},{"key":"R33-11-20210206","first-page":"545","article-title":"The genetic determinants of atorvastatin response","volume":"9","author":"Rodrigues","year":"2007","journal-title":"Curr Opin Mol Ther"},{"key":"R34-11-20210206","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/BOR.0b013e328314b7b4","article-title":"Genetic predisposition to statin myopathy","volume":"20","author":"Vladutiu","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"R35-11-20210206","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nrd2423","article-title":"Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges","volume":"6","author":"Wilke","year":"2007","journal-title":"Nature Rev Drug Discov"},{"key":"R36-11-20210206","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1345\/aph.10228","article-title":"Rhabdomyolysis and HMG-CoA reductase inhibitors","volume":"35","author":"Omar","year":"2001","journal-title":"Ann Pharmacother"},{"key":"R37-11-20210206","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"R38-11-20210206","doi-asserted-by":"crossref","first-page":"348","DOI":"10.2165\/00003088-199631050-00003","article-title":"Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors","volume":"31","author":"Desager","year":"1996","journal-title":"Clin Pharmacokinet"},{"key":"R39-11-20210206","first-page":"637","article-title":"HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles","volume":"40","author":"Beaird","year":"2000","journal-title":"J Am Pharm Assoc"},{"key":"R40-11-20210206","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11745-007-3142-5","article-title":"Oral nanoparticulate atorvastatin calcium is more efficient and safe in comparison to Lipicure\u00ae in treating hyperlipidemia","volume":"43","author":"Meena","year":"2008","journal-title":"Lipids"},{"key":"R41-11-20210206","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2165\/00003088-200847070-00003","article-title":"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin","volume":"47","author":"Neuvonen","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"R42-11-20210206","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1001\/archneur.1986.00520050091033","article-title":"Chronic human colchicine neuropathy and myopathy","volume":"43","author":"Riggs","year":"1986","journal-title":"Arch Neurol"},{"key":"R43-11-20210206","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1056\/NEJM198706183162502","article-title":"Colchicine myopathy and neuropathy","volume":"316","author":"Kuncl","year":"1987","journal-title":"N Engl J Med"},{"key":"R44-11-20210206","first-page":"264","article-title":"Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout","volume":"18","author":"Wallace","year":"1991","journal-title":"J Rheumatol"},{"key":"R45-11-20210206","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0014-4827(03)00034-X","article-title":"Exocytotic \u2018constipation\u2019 is a mechanism of tubulin\/lysosomal interactions in colchicine myopathy","volume":"285","author":"Kuncl","year":"2003","journal-title":"Exp Cell Res"},{"key":"R46-11-20210206","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00002826-200209000-00008","article-title":"Colchicine-induced acute myopathy in a patient with concomitant use of simvastatin","volume":"25","author":"Hsu","year":"2002","journal-title":"Clin Neuropharmacol"},{"key":"R47-11-20210206","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/mus.20135","article-title":"Cytoskeletal myotoxicity from simvastatin and colchicine","volume":"30","author":"Baker","year":"2004","journal-title":"Muscle Nerve"},{"key":"R48-11-20210206","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0006-2952(96)00693-4","article-title":"Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation","volume":"53","author":"Tateishi","year":"1997","journal-title":"Biochem Pharmacol"},{"key":"R49-11-20210206","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2165\/00002018-200022060-00003","article-title":"HMG-CoA reductase inhibitors and myotoxicity","volume":"22","author":"Ucar","year":"2000","journal-title":"Drug Saf"},{"key":"R50-11-20210206","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1002\/art.1780351218","article-title":"Rapid-onset colchicine myoneuropathy","volume":"35","author":"Schiff","year":"1992","journal-title":"Arthritis Rheum"},{"key":"R51-11-20210206","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/0140-6736(91)91294-5","article-title":"Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy","volume":"337","author":"Arnaudo","year":"1991","journal-title":"Lancet"},{"key":"R52-11-20210206","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nm0595-417","article-title":"Mitochondrial toxicity of antiviral drugs","volume":"1","author":"Lewis","year":"1995","journal-title":"Nat Med"},{"key":"R53-11-20210206","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jns.2007.10.026","article-title":"Effects of short-term zidovudine exposure on mitochondrial DNA content and succinate dehydrogenase activity of rat skeletal muscle cells","volume":"268","author":"Kiyomoto","year":"2008","journal-title":"J Neurol Sci"},{"key":"R54-11-20210206","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1056\/NEJMoa010581","article-title":"Wild-mushroom intoxication as a cause of rhabdomyolysis","volume":"345","author":"Bedry","year":"2001","journal-title":"N Engl J Med"},{"key":"R55-11-20210206","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/153537020623100213","article-title":"Suspected myotoxicity of edible wild mushrooms","volume":"231","author":"Nieminen","year":"2006","journal-title":"Exp Biol Med"},{"key":"R56-11-20210206","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/ajcn\/69.2.231","article-title":"Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement","volume":"69","author":"Heber","year":"1999","journal-title":"Am J Clin Nutr"},{"key":"R57-11-20210206","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1097\/00007890-200210270-00028","article-title":"Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient","volume":"74","author":"Prasad","year":"2002","journal-title":"Transplantation"},{"key":"R58-11-20210206","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.amjcard.2008.02.056","article-title":"Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction","volume":"101","author":"Lu","year":"2008","journal-title":"Am J Cardiol"},{"key":"R59-11-20210206","doi-asserted-by":"crossref","first-page":"758","DOI":"10.4065\/83.7.758","article-title":"Simvastatin vs therapeutic lifestyle changes and supplements: randomized primary prevention trial","volume":"83","author":"Becker","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"R60-11-20210206","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1365-2125.2008.03224.x","article-title":"Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian Surveillance System of Natural Health Products","volume":"66","author":"Lapi","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"R61-11-20210206","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1097\/01.SMJ.0000100117.79718.DC","article-title":"Chinese red rice-induced myopathy","volume":"96","author":"Smith","year":"2003","journal-title":"South Med J"},{"key":"R62-11-20210206","doi-asserted-by":"crossref","first-page":"474","DOI":"10.7326\/0003-4819-145-6-200609190-00021","article-title":"Symptomatic myopathy due to red yeast rice","volume":"145","author":"Mueller","year":"2006","journal-title":"Ann Intern Med"},{"key":"R63-11-20210206","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"R64-11-20210206","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1345\/aph.1K077","article-title":"Gabapentin-induced severe myopathy","volume":"41","author":"Tuccori","year":"2007","journal-title":"Ann Pharmacother"}],"container-title":["Current Opinion in Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/WCO.0b013e32833045a0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:57:48Z","timestamp":1786039068000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00019052-200910000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/wco.0b013e32833045a0","relation":{},"ISSN":["1350-7540"],"issn-type":[{"value":"1350-7540","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}